Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01819194
Other study ID # CR-5282
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2013
Est. completion date August 2013

Study information

Verified date May 2016
Source Johnson & Johnson Vision Care, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial aims to establish a correlation between patient reported comfort while using soft contact lenses and meibomian gland dysfunction (MGD).


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date August 2013
Est. primary completion date August 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria:

1. The subject must be able to read, understand, and sign the statement of informed consent and receive a fully executed copy of the form.

2. The subject be able and willing to adhere to the instructions set forth in this clinical protocol.

3. The subject must be 18 and less than 39 years of age.

4. The subject must be an adapted soft contact lens wearer in both eyes (Defined as having been a full times lens wearer for at least 3 months).

5. Subjects must be current full time daily wearers of Acuvue Oasys lenses (defined as, at least 6 hours per day, 5 days per week).

6. The subject's spherical equivalent distance refraction must be in the range of 0.00 to -6.00D in each eye.

7. The subject must present at visit 1 with a current copy of their spectacle prescription.

8. The subject must have the best corrected visual acuity of 0.18 or better in each eye as assessed by LogMAR chart.

9. The subject must have normal eyes (i.e., no ocular medication, or infections of any type)

Exclusion Criteria:

1. Wear Acuvue Oasys with Hydraclear Plus on an extended wear basis.

2. Wear Acuvue Oasys with Hydraclear Plus for astigmatism.

3. History of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia, active or recent varicella, viral disease of the cornea and/or conjunctiva; chronic bacterial disease of the cornea and/or conjunctiva; mycobacterial infection of the eye; and/or fungal disease of the eye.

4. Use of concomitant ocular medications during the study period. Topical artificial tears or contact lens lubricants are allowed, but no instillation on the day of examinations.

5. Any systemic disease, autoimmune disease, or use of medications, which may interfere with contact lens wear.

6. Subjects using medications influencing tear production such as steroids, immunosuppressive agents and/or anti-cholinergics (e.g. cold and allergy medications, tricyclic antidepressants) for treatment of autoimmune connective tissue disease may not be enrolled in this study if they have not been on a stable dosing regimen for 30 days prior to the Eligibility Visit. Subjects may use birth control medications since there is inconclusive evidence relative to the influence on tear film.

7. Any infectious disease (e.g. Hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV, by self report).

8. Subjects reporting discomfort at screening visit related to fit or care system abnormalities (both determined by the investigator), ocular conditions such as conjunctival infections, iritis.

9. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).

10. Any ocular or systemic allergies or diseases that may interfere with contact lens wear.

11. Entropion, ectropion, extrusion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosion,aphakia, or moderate or above corneal distortion by keratometry.

12. Any previous, or planned, ocular or intraocular surgery (radial keratotomy, LASIK, ETC.)

13. Any grade 3 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g. past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.

14. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.

15. Monovision or multi-focal contact lens correction

16. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment

17. History of binocular vision abnormality or strabismus

18. History of serious mental illness

19. History of seizures

Study Design


Related Conditions & MeSH terms


Intervention

Device:
senofilcon A


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson Vision Care, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comfort as Measured by the Contact Lens Users Experience Questionnaire (CLUE) CLUE is survey that is used to assess subjective comfort of the test article. The higher the score the better on a range of 0 to 120. Post 3 days of wear
Primary Meibbomian Gland Dysfunction (MGD)as Measured by MGD Scale Meibomian Gland Dysfunction (MGD) as measured using the MGD 0 - 11 scale translated into grades 0 to 3 where 0 refers to absence of markers. Post 3 days of wear
See also
  Status Clinical Trial Phase
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT04884243 - Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Terminated NCT02596919 - Fast Infrared Meibography (Photography) N/A
Completed NCT01207752 - The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction N/A
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT03652051 - A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED) Phase 2
Recruiting NCT03767530 - Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction N/A
Active, not recruiting NCT05577910 - Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD N/A
Completed NCT04889950 - Clinical Study to Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction N/A
Recruiting NCT06004895 - Mechanisms of Light-based Therapies for Dry Eye Disease N/A
Completed NCT04147962 - Intense Pulsed Light in Meibomian Gland Dysfunctions
Completed NCT02256969 - Intraductal Meibomian Gland Probing Trial Phase 4
Recruiting NCT05089591 - Intense Pulsed Light in Meibomian Gland Dysfunction N/A
Completed NCT04500821 - Evaluation of the LipiFlow System With a New Activator N/A
Completed NCT03318874 - Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction Phase 4
Completed NCT06278584 - iLux Treatment for Meibomian Gland Dysfunction N/A
Recruiting NCT04052841 - Morphological Analysis of Meibomian Glands N/A
Completed NCT05028491 - The Influence of Meibomian Gland Expression on Corneal Aberrations in MGD Patients